Faculty Opinions recommendation of LDL cholesterol reduction in elderly patients with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726104259.793512964 ◽

2016 ◽

Author(s):

Nanette Wenger

Keyword(s):

Monoclonal Antibody ◽

Elderly Patients ◽

Ldl Cholesterol ◽

Pooled Analysis ◽

Phase 2 ◽

Cholesterol Reduction ◽

Open Label ◽

Open Label Extension

Download Full-text

LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIES

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(15)61366-3 ◽

2015 ◽

Vol 65 (10) ◽

pp. A1366 ◽

Cited By ~ 6

Author(s):

Michael Koren ◽

Robert Rosenson ◽

Bobby Khan ◽

Narimon Honarpour ◽

Mary Elliott ◽

...

Keyword(s):

Monoclonal Antibody ◽

Elderly Patients ◽

Ldl Cholesterol ◽

Pooled Analysis ◽

Phase 2 ◽

Cholesterol Reduction ◽

Open Label ◽

Open Label Extension

Download Full-text

Faculty of 1000 evaluation for LDL cholesterol reduction in elderly patients with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.726057373.793512964 ◽

2016 ◽

Author(s):

Nanette Wenger

Keyword(s):

Monoclonal Antibody ◽

Elderly Patients ◽

Ldl Cholesterol ◽

Pooled Analysis ◽

Phase 2 ◽

Cholesterol Reduction ◽

Open Label ◽

Open Label Extension

Download Full-text

128 SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS

Gastroenterology ◽

10.1016/s0016-5085(21)00831-3 ◽

2021 ◽

Vol 160 (6) ◽

pp. S-35

Author(s):

Geert R. D'Haens ◽

Jean Frederic Colombel ◽

Gary R. Lichtenstein ◽

Lorna Charles ◽

AnnKatrin Petersen ◽

...

Keyword(s):

Ulcerative Colitis ◽

Pooled Analysis ◽

Active Ulcerative Colitis ◽

Phase 2 ◽

Open Label ◽

Phase 3 ◽

Open Label Extension ◽

Over Time

Download Full-text

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2012.04705.x ◽

2012 ◽

pp. no-no ◽

Cited By ~ 8

Author(s):

R.G. Langley ◽

K. Papp ◽

A.B. Gottlieb ◽

G.G. Krueger ◽

K. B. Gordon ◽

...

Keyword(s):

Monoclonal Antibody ◽

Clinical Trials ◽

Phase Ii ◽

Pooled Analysis ◽

Interleukin 12 ◽

Open Label ◽

Randomized Controlled ◽

Open Label Extension ◽

Phase Ii And Iii ◽

Extension Trial

Download Full-text

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Case Medical Research ◽

10.31525/ct1-nct04257929 ◽

2020 ◽

Author(s):

Keyword(s):

Prader Willi Syndrome ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Open Label Extension

Download Full-text

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

Neuromuscular Disorders ◽

10.1016/j.nmd.2021.02.001 ◽

2021 ◽

Author(s):

Richard S. Finkel ◽

Erika Finanger ◽

Krista Vandenborne ◽

H. Lee Sweeney ◽

Gihan Tennekoon ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Phase 2 ◽

Open Label ◽

Open Label Extension ◽

Disease Modifying ◽

Extension Trial

Download Full-text

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

Dermatology and Therapy ◽

10.1007/s13555-021-00490-3 ◽

2021 ◽

Author(s):

Kim A. Papp ◽

Saskia de Vente ◽

Jiewei Zeng ◽

Mary Flack ◽

Byron Padilla ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70037-8 ◽

2013 ◽

Vol 14 (4) ◽

pp. 354-362 ◽

Cited By ~ 26

Author(s):

Jorge Cortes ◽

Eric Feldman ◽

Karen Yee ◽

David Rizzieri ◽

Anjali S Advani ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Dosing Regimens ◽

Acute Myeloid

Download Full-text

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

Annals of Oncology ◽

10.1093/annonc/mdw373.74 ◽

2016 ◽

Vol 27 ◽

pp. vi294

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Neoadjuvant Therapy ◽

Bladder Carcinoma ◽

Phase 2 ◽

Open Label ◽

Urothelial Bladder Carcinoma ◽

Programmed Death ◽

Phase 2 Study ◽

Urothelial Bladder ◽

Muscle Invasive

Download Full-text

25853 Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.313 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB72

Author(s):

Elke Weisshaar ◽

Jacek C. Szepietowski ◽

Thomas R. Sciascia ◽

Gil Yosipovitch ◽

Sonja Ständer

Keyword(s):

Randomized Controlled Trial ◽

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Open Label Extension

Download Full-text